Diffuse Large B Cell Lymphoma: A Single Centre Study.

BACKGROUND : Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of B-cell lymphoma with variation in patient survival. Information regarding clinical presentation, staging, prognostic determinant (biological [GCB, non-GCB] and clinical[IPI]), and response to chemotherapy (CHOP and Rituximab CHOP) in exclusively nodal cases of DLBCL is limited. AIMS AND OBJECTIVES: To analyse the response to chemotherapy (CHOP and Rituximab CHOP) and to access the prognostic significance of IPI and biological subgrouping of nodal DLBCL cases in our institution. METHODS : All patients with nodal DLBCL cases who underwent treatment with minimum six months follow up in the Department of Haematology between January 2006 and April 2010 and whose slides and blocks could be retrieved from Department of Pathology were included in the study. RESULTS: Of the 106 patients, 71(67%) male and 78(73.6%) patients were